Impact of belantamab mafodotin‐induced ocular toxicity on outcomes of patients with advanced multiple myeloma
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18298
Abstract: Belantamab mafodotin (BLMF) is a B‐cell maturation antigen‐directed antibody‐drug conjugate, recently approved for advanced multiple myeloma (MM). The impact of BLMF‐induced ocular toxicity on patient outcomes is unknown. We studied a cohort of 38 consecutively… read more here.
Keywords: advanced multiple; belantamab mafodotin; blmf; toxicity ... See more keywords
Treatment of locally advanced or multiple basal cell carcinoma with vismodegib in real world setting.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e22065
Abstract: e22065Background: Evaluation of efficacy and safety of vismodegib (V) was done in a retrospective analysis of patients (pts) with locally advanced or multiple basal cell carcinoma (laBCC or multipl... read more here.
Keywords: advanced multiple; cell carcinoma; vismodegib; basal cell ... See more keywords